NC
NTLA icon

nVerses Capital’s Intellia Therapeutics NTLA Stock Holding History

nVerses Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,900
Closed -$142K – 587
2024
Q3 		$142K Buy
+6,900
New +$159K 0.06% 407
2024
Q2 		– Sell
-1,100
Closed -$30.3K – 1145
2024
Q1 		$30.3K Buy
+1,100
New +$30.6K 0.07% 343

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

nVerses Capital's NTLA Position: Q4 2024 in Review

nVerses Capital sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 6,900 shares — an estimated $142K sold.

nVerses Capital first reported a position in NTLA in Q1 2024 and held it in 2 quarters. The position peaked at $142K in Q3 2024. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • nVerses Capital reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 6,900 Intellia Therapeutics shares in Q4 2024, an estimated $142K.
  • nVerses Capital first reported a position in Intellia Therapeutics in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's Intellia Therapeutics position peaked at $142K in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.